S&P Futures
5,909.25 +3.25 (+0.06%) Dow Futures
43,549.00 +31.00 (+0.07%) Nasdaq Futures
20,487.50 +4.00 (+0.02%) Russell 2000 Futures
2,294.50 +3.30 (+0.14%) Crude Oil
69.53 +0.31 (+0.45%) Gold
2,746.60 +16.60 (+0.61%)
METheraHld (METX.CN)
- Newsfile
ME Therapeutics Announces the Start of Testing of First mRNA Formulations from NanoVation Therapeutics Collaboration
Vancouver, British Columbia--(Newsfile Corp. - September 18, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce the start of efficacy testing of the first two mRNA formulations from its strategic collaboration with NanoVation Therapeutics Inc. ("NanoVation Therapeutics"). As previously disclosed, ME Therapeutics a
- Newsfile
ME Therapeutics Announces New Collaboration with NanoVation Therapeutics on Advanced Therapeutic mRNA Delivery to Myeloid Cells
Vancouver, British Columbia--(Newsfile Corp. - July 8, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce a strategic collaboration with NanoVation Therapeutics Inc. ("NanoVation Therapeutics"). This partnership aims to test the delivery and efficacy of mRNA-based drug candidates targeted to myeloid cells.ME Thera
